N Engl J Med. 2012 Jun 7; 366(23):2151-60
Delamanid is a nitro-dihdro-imidazooxazole derivative that inhibits mycolic acid synthesis. In this study, delamanid was given at one of two doses in addition to 'background' tuberculosis (TB) therapy consisting of multiple other drugs for patients with multidrug resistant (MDR) TB, that is, TB resistant to at least isoniazid and...
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.
Subscribe for $9.95/monthSend a recommendation to your institution's librarian or information manager to request an extended free trial for all users.
Recommend to your LibrarianIf you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.
Request an Institutional Trialyour institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.
If you think you should be able to access this content, please contact us.
